Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBIT (2023 - 2026)

Contineum Therapeutics' EBIT history spans 4 years, with the latest figure at -$16.9 million for Q1 2026.

  • Quarterly EBIT rose 6.66% to -$16.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$66.9 million through Mar 2026, down 13.17% year-over-year, with the annual reading at -$68.1 million for FY2025, 33.73% down from the prior year.
  • EBIT came in at -$16.9 million for Q1 2026, up from -$17.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $38.9 million in Q2 2023 to a low of -$20.9 million in Q4 2023.
  • The 4-year median for EBIT is -$14.9 million (2025), against an average of -$10.1 million.
  • The largest YoY upside for EBIT was 18.31% in 2024 against a maximum downside of 128.11% in 2024.
  • Contineum Therapeutics' EBIT stood at -$20.9 million in 2023, then grew by 18.31% to -$17.0 million in 2024, then dropped by 0.4% to -$17.1 million in 2025, then grew by 1.23% to -$16.9 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's EBIT are -$16.9 million (Q1 2026), -$17.1 million (Q4 2025), and -$14.9 million (Q3 2025).